You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
X Demographics
Mendeley readers
Attention Score in Context
| Title |
Recent Advances of Cell-Cycle Inhibitor Therapies for Pediatric Cancer
|
|---|---|
| Published in |
Cancer Research, November 2017
|
| DOI | 10.1158/0008-5472.can-17-2066 |
| Pubmed ID | |
| Authors |
Christopher C. Mills, EA. Kolb, Valerie B. Sampson |
| Abstract |
This review describes the pivotal roles of cell-cycle and checkpoint regulators and discusses development of specific cell-cycle inhibitors for therapeutic use for pediatric cancer. The mechanism of action as well as the safety and tolerability of drugs in pediatric patients, including compounds that target CDK4/CDK6 (palbociclib, ribociclib, and abemaciclib), aurora kinases (AT9283 and MLN8237), Wee1 kinase (MK-1775), KSP (ispinesib), and tubulin (taxanes, vinca alkaloids), are presented. The design of mechanism-based combinations that exploit the cross-talk of signals activated by cell-cycle arrest, as well as pediatric-focused drug development, are critical for the advancement of drugs for rare childhood diseases. Cancer Res; 1-10. ©2017 AACR. |
X Demographics
The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 1 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 1 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 121 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 121 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Ph. D. Student | 27 | 22% |
| Researcher | 13 | 11% |
| Student > Bachelor | 13 | 11% |
| Student > Master | 12 | 10% |
| Student > Postgraduate | 6 | 5% |
| Other | 14 | 12% |
| Unknown | 36 | 30% |
| Readers by discipline | Count | As % |
|---|---|---|
| Biochemistry, Genetics and Molecular Biology | 33 | 27% |
| Medicine and Dentistry | 18 | 15% |
| Agricultural and Biological Sciences | 12 | 10% |
| Chemistry | 6 | 5% |
| Immunology and Microbiology | 4 | 3% |
| Other | 9 | 7% |
| Unknown | 39 | 32% |
Attention Score in Context
This research output has an Altmetric Attention Score of 4. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 07 December 2022.
All research outputs
#7,400,159
of 23,292,144 outputs
Outputs from Cancer Research
#7,564
of 18,071 outputs
Outputs of similar age
#145,647
of 439,454 outputs
Outputs of similar age from Cancer Research
#101
of 178 outputs
Altmetric has tracked 23,292,144 research outputs across all sources so far. This one has received more attention than most of these and is in the 67th percentile.
So far Altmetric has tracked 18,071 research outputs from this source. They typically receive more attention than average, with a mean Attention Score of 8.8. This one has gotten more attention than average, scoring higher than 57% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 439,454 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 66% of its contemporaries.
We're also able to compare this research output to 178 others from the same source and published within six weeks on either side of this one. This one is in the 43rd percentile – i.e., 43% of its contemporaries scored the same or lower than it.